SCHEMBL2376620

SCHEMBL2376620

N#C/N=C1\CC(c2cccnc2)Oc2ccc(-c3cccc(C#N)c3)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.39
CHRNA5 P30532 2/20 0.39
CHRNA4 P43681 2/20 0.39
CYP11B2 P19099 6/20 0.38
CYP11B1 P15538 4/20 0.38
CYP17A1 P05093 1/20 0.38
NEK1 Q96PY6 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
CYP19A1 P11511 2/20 0.36
VCP P55072 1/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2C19 P33261 3/20 0.35
CYP1A2 P05177 2/20 0.35
HSD17B10 Q99714 2/20 0.35
KCNA5 P22460 2/20 0.35
KCNH2 Q12809 2/20 0.35
CYP2C9 P11712 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2376622 1.00 CHRNB2 (0.39) CHRNB2CHRNA5CHRNA4CYP11B2CYP11B1
SCHEMBL1821928 0.86 CYP19A1 (0.47) CHRNB2CHRNA5CHRNA4CYP11B2CYP11B1
SCHEMBL12245742 0.86 KDM4E (0.35) CYP11B2CYP11B1ALDH1A1KDM4ELMNA
SCHEMBL1822367 0.82 GRM5 (0.40) CLK4
SCHEMBL1822368 0.82 GRM5 (0.40) CLK4
SCHEMBL1822899 0.82 ALDH1A1 (0.40) CYP11B2CYP11B1ALDH1A1KDM4ELMNA
SCHEMBL1822900 0.82 ALDH1A1 (0.40) CYP11B2CYP11B1ALDH1A1KDM4ELMNA
SCHEMBL1822439 0.72 CYP19A1 (0.43) KDM4ECYP19A1HSD17B10
SCHEMBL1824011 0.72 BACE1 (0.37)
SCHEMBL1824010 0.72 BACE1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2013-11-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP CHRNB2 351/4885CHRNA5 479/4885CHRNA4 985/4885
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, APP CHRNB2 351/4885CHRNA5 479/4885CHRNA4 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.